BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $9,391 | +874.2% | 1,126 | +1240.5% | 0.00% | – |
| Q4 2022 | $964 | -3.6% | 84 | -24.3% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 111 | +32.1% | 0.00% | – |
| Q2 2022 | $1,000 | -99.5% | 84 | -99.3% | 0.00% | – |
| Q1 2022 | $197,000 | +22.4% | 12,100 | +4.3% | 0.00% | – |
| Q4 2021 | $161,000 | +30.9% | 11,600 | +35.0% | 0.00% | – |
| Q3 2021 | $123,000 | -7.5% | 8,594 | +2.3% | 0.00% | – |
| Q2 2021 | $133,000 | +14.7% | 8,400 | -26.3% | 0.00% | – |
| Q1 2021 | $116,000 | +673.3% | 11,400 | +470.0% | 0.00% | – |
| Q4 2020 | $15,000 | +200.0% | 2,000 | +100.0% | 0.00% | – |
| Q2 2020 | $5,000 | -61.5% | 1,000 | -78.5% | 0.00% | – |
| Q3 2019 | $13,000 | -27.8% | 4,648 | 0.0% | 0.00% | – |
| Q2 2019 | $18,000 | +500.0% | 4,648 | +1243.4% | 0.00% | – |
| Q1 2019 | $3,000 | 0.0% | 346 | -9.9% | 0.00% | – |
| Q1 2015 | $3,000 | -40.0% | 384 | 0.0% | 0.00% | – |
| Q4 2014 | $5,000 | +25.0% | 384 | 0.0% | 0.00% | – |
| Q3 2014 | $4,000 | – | 384 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |